MITO23: Phase III Trial of Trabectedin vs Investigator’s Choice of Chemotherapy for Recurrent Ovarian Cancer With BRCA Mutation or BRCAness Phenotype

Source: 2022 ASCO Annual Meeting*
Download Slideset
June 3-7, 2022; Chicago, Illinois
In MITO23, trabectedin failed to improve survival compared with investigator’s choice of single-agent chemotherapy in patients with BRCA-mutant or BRCAness phenotype recurrent ovarian cancer.
Format: Microsoft PowerPoint (.ppt)
File Size: 136 KB
Released: June 17, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline
Merck Sharp & Dohme Corp.
Seagen & Genmab

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings